CSBio CSBio

X
[{"orgOrder":0,"company":"Green Valley Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Green Valley to Start US Trials of Algae-Based Alzheimer\u2019s Drug","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"CHINA","productType":"Small molecule","productStatus":"Approved","date":"April 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Green Valley Pharmaceuticals"},{"orgOrder":0,"company":"Jemincare","sponsor":"Orion Pharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$15.8 million","newsHeadline":"Orion Enters Into Exclusive Agreement with Jemincare for Novel Non-Opioid Drug Candidate for The Treatment of Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Jemincare"},{"orgOrder":0,"company":"Jemincare","sponsor":"Orion Corporation","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$16.1 million","newsHeadline":"Orion and Jemincare Enter Into an Exclusive Agreement Regarding a Non-Opioid Drug Candidate for The Treatment of Pain","therapeuticArea":"Neurology","highestDevelopmentStatus":"IND Enabling","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Jemincare"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            According to the agreement, Orion has the right to develop and commercialise the JMKX000623, NaV 1.8 blocker asset in its territory. Orion will be fully responsible for its own development and commercialisation costs.

            Lead Product(s): JMKX000623

            Therapeutic Area: Neurology Product Name: JMKX000623

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: Orion Pharma

            Deal Size: Undisclosed Upfront Cash: $15.8 million

            Deal Type: Agreement May 06, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            According to the agreement, Orion has the right to develop and commercialize the drug precursor in its own territory. JMKX000623 is a potent and selective Nav1.8 blocker independently developed by Jemincare.

            Lead Product(s): JMKX000623

            Therapeutic Area: Neurology Product Name: JMKX000623

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: Orion Corporation

            Deal Size: Undisclosed Upfront Cash: $16.1 million

            Deal Type: Agreement May 06, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Green Valley Pharma’s scientists have suggested that GV-971 may work by altering the balance of microorganisms in the GI tract that contribute to inflammation in the central nervous system.

            Lead Product(s): Sodium oligomannate

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: IND Enabling Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable April 27, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY